Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Receivables: 2024-2025

Historic Change in Receivables for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $14.0 million.

  • ARS Pharmaceuticals' Change in Receivables rose 1712.03% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year change of. This contributed to the annual value of $8.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Change in Receivables is $14.0 million, which was up 5.74% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Change in Receivables registered a high of $14.0 million during Q3 2025, and its lowest value of $773,000 during Q3 2024.
  • Its 2-year average for Change in Receivables is $7.3 million, with a median of $7.4 million in 2024.
  • Data for ARS Pharmaceuticals' Change in Receivables shows a peak YoY spiked of 1,712.03% (in 2025) over the last 5 years.
  • Over the past 2 years, ARS Pharmaceuticals' Change in Receivables (Quarterly) stood at $7.4 million in 2024, then spiked by 1,712.03% to $14.0 million in 2025.
  • Its Change in Receivables stands at $14.0 million for Q3 2025, versus $13.2 million for Q2 2025 and $1.1 million for Q1 2025.